AzTrials
AzTrials

AphasiaVoiceAdaptNCT04108364

Voice Adaptive Tablet-Based Naming Treatment for Adults With Aphasia

A study testing Voice adaptive training for aphasia in people with Aphasia, run by University of Alberta at 2 sites in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Rising life expectancy is leading to a rising incidence of strokes worldwide. Approximately one third of people who had a stroke live with a communication disorder, aphasia, which is associated with the largest negative relationship to quality of life. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Aphasia
What is being tested?
Voice adaptive training for aphasia
Could I receive a placebo?
No, everyone receives an active treatment
How many people
38 participants
Where
2 sitesCanada
Study dates
1 Oct 2020to 5 Jan 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • be at least 6 months post onset of a single stroke in the left hemisphere
  • have aphasia of mild to moderate severity (Aphasia Quotient ≥ 30 on WAB--R) with a prominent verbal expression impairment.
  • pass screenings of visual perception (BORB), hearing (pure tone screening with portable audiometer), and basic cognitive functioning (Raven's Coloured Progressive Matrices)
  • speak English as a primary language.
  • be willing to commit to participation for study duration

Who cannot join

  • Currently participating in individual (one-on-one) speech-language therapy

Trial locations and contacts

2 sites in 1 country.

Canada2 sites
  • University of Alberta

    Edmonton, Alberta, T6G2G4

  • University of Toronto

    Toronto, Ontario, M5G 1V7

Other trials in Canada

About this study

Official title: Voice Adaptive Training for Adults With Aphasia

Rising life expectancy is leading to a rising incidence of strokes worldwide. Approximately one third of people who had a stroke live with a communication disorder, aphasia, which is associated with the largest negative relationship to quality of life. In chronic stages, people with aphasia (PwA) often do not receive any rehabilitation, despite treatment being shown to significantly reduce impairment. In contrast to existing computerized aphasia treatment, VoiceAdapt is an innovative and motivating application for PwA that provides adaptive and context-aware training lessons via speech interaction on the mobile device. A user-centred design process and motivational gamification ensure long-term engagement in training. Through providing an autonomously usable and low-cost tool, VoiceAdapt will positively affect PwA's self-esteem and social inclusion, leading to higher quality of life.

Read the detailed description

Purpose:

The purpose of the study proposed in this ethics application is to examine the impact of an adaptive speech-language treatment app, created using principles of user-centred design, on language and communication outcomes of people with aphasia (PwA) within a randomized controlled trial.

Background:

Nearly one third of individuals who have a stroke will present with aphasia, a communication impairment that affects the ability to speak, understand, read and write. People with aphasia (PwA) have been shown to demonstrate more limitations in their participation in daily activities, lower quality of life and a higher incidence of depression relative to post-stroke individuals without aphasia, even when other factors such as physical ability, social support and well-being were similar.

The overall goals of the VoiceAdapt research project are to: 1) conduct a needs survey with PwA and speech-language pathologists (SLPs); 2) develop an app employing a user-centred design process; and 3) conduct a randomized controlled trial. Using user-centred design, end users and stakeholders (PwA, therapists and formal/informal caregivers) will be engage din a needs survey during the technology development process. Outcomes will be analyzed to elaborate implications for decision makers as to how to implement such adaptive training environments in stroke rehabilitation. This aspect of the research (i.e., Goals 1 \& 2) will be carried out by consortium members in Austria and Germany. Only the randomized controlled trial (Goal 3), which is the subject of the present application, will be conducted at the University of Alberta and the University of Toronto.

PwA will be provided with a personalized speech-language treatment app (i.e., on a tablet), which automatically adapts the exercises to the users' actual skill level. Individual learning progress of PwA will be supported by personalized and gamified training elements to achieve higher compliance and adherence to the exercises. As a primary outcome, the adaptive assistive technology will examine language performance related to the specific intervention of the personalized speech-language treatment app. Additional objectives will examine the change in the overall language and communication functioning of PwA; the well-being and quality of life of PwA and their caregiver's perception of communication effectiveness after intervention with the treatment app.

The research will be carried out by the VoiceAdapt Consortium, which brings together the resources of five participating international institutions. Research partners have expertise in the fields of technology/e-health and graphical design skills (Nurogames, NG), personalization and adaptvitiy (Technical University of Berlin, TUB), user-centred design and gamification/persuasion (Austrian Institute of Technology, AIT), and clinical research and intervention studies (University of Toronto, UoT; University of Alberta, UoA).

Research Methods/Procedures:

Researchers at the University of Alberta and University of Toronto will be the primary investigators of the randomized controlled trial (RCT) portion of the VoiceAdapt Project. The RCT will involve 80 PwA in total across University of Alberta and University of Toronto sites.

Design of the RCT: The RCT will be a two arm, randomized, waitlist-controlled, crossover group design. In Phase 1, PWA randomized to the intervention group will train with VoiceAdapt. The control group will be a waitlist treatment-deferred group. In Phase 2, the control group will train with VoiceAdapt. The randomization of participants will be achieved by computer-generated assignment.

Participants: All participants will have suffered a left hemisphere stroke, be at least 6 months post-onset, and will have aphasia as defined by performance on the Western Aphasia Battery - Rev. (Aphasia Quotient greater than or equal to 30, with a prominent verbal expression impairment), but type of aphasia will not be an inclusion criterion. Participants will speak English as their primary language, pass screenings of visual perception, hearing and basic cognitive functioning and be willing to commit to participation for the study duration.

Intervention: Each intervention phase will last for 5 weeks. During this period, participants in the experimental condition will be asked to do speech language tasks 5 days a week for 60 minutes via the VoiceAdapt app (intervention group). The control group will not be engaged in any one on one speech therapy during the first intervention phase (Phase 1). During the second intervention phase (Phase 2), the control group will participate in training with the VoiceAdapt app (60 minutes/day x 5 days/week) and the intervention group from Phase 1 will crossover into receiving no treatment. Research staff will check in with individuals in the intervention group on a weekly basis to monitor and adjust treatment exercises. Research staff will check in with participants in the control group twice during their respective control phase.

Outcome Measures: In line with the recommended core outcome measures for aphasia research (Wallace et al., 2019), participants in both groups will be tested before and after each condition on the following measures: the primary outcome measure will be the Boston Naming Test (BNT) to measure naming; secondary outcome measures will be: Western Aphasia Battery-Revised (WAB-R); Stroke and Aphasia Quality of Life Scale (SAQOL-39) to measure quality of life; and Communication Effectiveness Index (CETI) to measure the person with aphasia and the partners' perception of the participant's communication. In addition to these measures, the Situational Motivation Scale (SIMS) and an end of study questionnaire will be provided to all participants.

Plan for Data Analysis:

The primary analysis will be a one-sided hypothesis test of the null hypothesis of the change in naming on the Boston Naming Test (BNT) from baseline to week 6, tested at the 0.1 level of significance. The observed change on the BNT as well as the baseline, 6 week and follow up values will be summarized for each group as means and standard deviations. Secondary outcomes will be summarized using means (SD), medians (IQR) or proportions (CI), and analyzed using t tests, as appropriate. All analyses will be presented in aggregate.

Conditions
Aphasia
Being tested
Voice adaptive training for aphasia
Keywords
aphasia, anomia, rehabilitation, speech-language pathology, mobile applications, language therapy, stroke, stroke rehabilitation
Medical subject headings
Aphasia, Anomia, Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Voice adaptive training for aphasiaBehavioural

    Training with the VoiceAdapt tablet-based therapy app 25 hours (1 hr/day x 5 days/week x 5 weeks)

Study groups in NCT04108364
Study groupRoleWhat they receive
VoiceAdapt InterventionExperimentalPWA who train with VoiceAdapt app
Receives: Behavioral: Voice adaptive training for aphasia
No InterventionNo interventionPWA who are on the waitlist and not training with VoiceAdapt app

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in naming on the Boston Naming Test (BNT)

    Naming performance (out of 60) on the BNT

    Measured: baseline; 7 weeks; 13 weeks

Secondary outcomes (3)
  1. Change in Aphasia Quotient on the Western Aphasia Battery-Revised (WAB-R)

    Score on the Aphasia Quotient (out of 100) portion of the WAB-R to measure general communication/language

    Measured: baseline; 7 weeks; 13 weeks

  2. Change in score on the Stroke and Aphasia Quality of Life Scale (SAQOL-39)

    Mean score (range = 1-5) on the SAQOL-39 to measure overall quality of life; higher scores indicate higher quality of life

    Measured: baseline; 7 weeks; 13 weeks

  3. Change in score on the Communication Effectiveness Index (CETI)

    Mean score (out of 100) of items on the CETI (16 questions) to measure partners' perception of the participant's communication; higher scores indicate higher communicative effectiveness

    Measured: baseline; 7 weeks; 13 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Sep 2019
  2. Study start1 Oct 2020
  3. Primary completion30 Sep 2022
  4. Study completion5 Jan 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
two arm, randomized, waitlist-controlled, crossover group design
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
38 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04108364
Sponsor's protocol ID
MYB155164
Acronym
VoiceAdapt
Status last verified
Jan 2023
First submitted
26 Sep 2019
Last updated
19 Sep 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Kim ES, Laird L, Wilson C, Stewart S, Mildner P, Moller S, Schatz R, Spang RP, Voigt-Antons JN, Rochon E. Outcomes of an App-Based Intervention to Target Naming Among Individuals With Poststroke Aphasia: Virtual Randomized Controlled Trial. JMIR Mhealth Uhealth. 2025 Aug 18;13:e67711. doi: 10.2196/67711.

    PubMed 40958192
  • Kim ES, Laird L, Wilson C, Bieg T, Mildner P, Moller S, Schatz R, Schwarz S, Spang R, Voigt-Antons JN, Rochon E. Implementation and Effects of an Information Technology-Based Intervention to Support Speech and Language Therapy Among Stroke Patients With Aphasia: Protocol for a Virtual Randomized Controlled Trial. JMIR Res Protoc. 2021 Jul 2;10(7):e30621. doi: 10.2196/30621.

    PubMed 34255727

Questions about this trial

What is this clinical trial studying?

A study testing Voice adaptive training for aphasia in people with Aphasia, run by University of Alberta at 2 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in naming on the Boston Naming Test (BNT) (time frame: baseline; 7 weeks; 13 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04108364, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in